SEC Form 4 · accession 0001144204-17-044233
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Walter V Klemp
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Aug 16, 2017
Accepted (ET)
Aug 18, 2017 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659617
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 16, 2017 | S | 100,000 | $1.703 | D | 967,724 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person entered into a private sale agreement for the shares of common stock set forth in the table. The 12,000 shares of common stock purchased by the reporting person on May 11, 2017 are a matching transaction under Section 16 of the Securities Exchange Act of 1934 with 12,000 shares of common stock sold by the reporting person as set forth in the table above. In Accordance with Section 16, the reporting person will disgorge to the issuer an aggregate short-swing profit of $10,716.
- F2In addition to the shares held directly by the reporting person, the reporting person is the majority shareholder and control person of Annamed, Inc. Annamed, Inc. holds 1,425,000 shares of Issuer common stock. The Pursuant to General Instruction 5(b)(iv) of Form 3, the amount set forth in the table represents the reporting person's proportionate interest in the Issuer common stock beneficially owned by Annamed, Inc.